Paul Heltzel on Muck Rack

Paul Heltzel

Virginia
As seen in: National Geographic, National Geographic Traveler, DNews, Computerworld, Computerworld Australia, CIO, InfoWorld, Network World, Data Center Knowledge, Cio Sweden and

Get in touch with Paul

Contact Paul, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

5 Minutes With T1D Scout Founder Yuta Matsuda

|
By Paul Heltzel
| diaTribe Verified
Type 1 diabetes screening typically requires a blood test. Geneticist Yuta Matsuda, founder of T1D Scout, developed an at-home test that starts with a saliva swab instead. If the test shows higher genetic risk, families can follow up with at-home antibody testing. Matsuda said the goal is to make screening easier to access and more likely to be completed – especially for families who may have trouble getting to a research site or completing a blood test with a young child.
Open in Who Shared Issue with article?

How To Cope With Diabetes Stigma at Work

|
By Paul Heltzel
| diaTribe Verified
People with diabetes sometimes hear comments from coworkers that can feel hurtful or judgmental. Routine care, like taking insulin or checking glucose, sometimes feels conspicuous, and coworkers' lack of understanding may leave people feeling like they're being judged, treated differently, or seen as less capable. Like others with diabetes, I've felt primarily acceptance and support from coworkers as I juggled type 1 along with my workload in half a dozen offices.
Open in Who Shared Issue with article?

Top Diabetes News: ADA 2026

|
By Anna Brooks, Andrew Saintsing, Paul Heltzel
| diaTribe Verified
Diabetes and Weight Management Treatments New Experimental Drug Leads To Dramatic Weight Loss and Relief From Related Conditions GLP-1-based medications have revolutionized blood sugar and weight management, but they aren’t effective for everyone. Eli Lilly, which makes the GLP-1/GIP drug Mounjaro (tirzepatide), is currently developing retatrutide, the first drug to target receptors for three hormones: GLP-1, GIP, and glucagon.
Open in Who Shared Issue with article?
See all 199 licensed articles (385 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified